Aura Biosciences (AURA) Net Cash Flow (2020 - 2026)
Aura Biosciences filings provide 7 years of Net Cash Flow readings, the most recent being $25.3 million for Q1 2026.
- Quarterly Net Cash Flow rose 286.1% to $25.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $46.8 million through Mar 2026, up 290.7% year-over-year, with the annual reading at $28.0 million for FY2025, 398.31% up from the prior year.
- Net Cash Flow hit $25.3 million in Q1 2026 for Aura Biosciences, up from $12.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $69.1 million in Q2 2025 and bottomed at -$83.1 million in Q1 2023.
- Average Net Cash Flow over 5 years is -$3.7 million, with a median of $6.3 million recorded in 2024.
- Peak annual rise in Net Cash Flow hit 1721.18% in 2025, while the deepest fall reached 1181.06% in 2025.
- Aura Biosciences' Net Cash Flow stood at $60.3 million in 2022, then plummeted by 124.08% to -$14.5 million in 2023, then skyrocketed by 143.29% to $6.3 million in 2024, then surged by 92.84% to $12.1 million in 2025, then soared by 108.75% to $25.3 million in 2026.
- Per Business Quant, the three most recent readings for AURA's Net Cash Flow are $25.3 million (Q1 2026), $12.1 million (Q4 2025), and -$59.8 million (Q3 2025).